Trial Profile

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary)
Indications Carcinoma; Peritoneal cancer
Focus Adverse reactions
Acronyms PIPAC-NAL-IRI

Most Recent Events

01 Jul 2025 Planned End Date changed from 1 Jan 2027 to 1 Apr 2027.
01 Jul 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Jan 2026.
14 Jul 2023 Timeframe for primary endpoints decreased from 18 weeks to 14 weeks.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com